Suppr超能文献

[心绞痛患者冠状动脉粥样硬化的血管造影过程。其与普萘洛尔、硝苯地平和硝酸盐治疗2年的关系]

[Angiographic course of coronary atherosclerosis in angina pectoris. Its relation to 2 years' treatment with propranolol, nifedipine and nitrates].

作者信息

Loaldi A, Fabbiocchi F, Montorsi P, Guazzi M, Polese A, De Cesare N, Ravagnani P, Guazzi M D

出版信息

Cardiologia. 1989 Nov;34(11):959-66.

PMID:2631989
Abstract

Calcium antagonists and beta-blockers may retard or inhibit atherogenesis. We tested whether nifedipine or propranolol may retard or induce regression of coronary atherosclerosis in man. In selected population of 113 patients with effort angina and proven coronary artery disease, the coronary cineangiographic pattern after 2 year therapy with nifedipine (Group 1, 39 patients), propranolol (Group 2, 36 patients), or isosorbide dinitrate (control group, 38 patients) was compared to the pre-treatment pattern. After 2 years the disease evolved to a different extent in the 3 groups. The number of lesions with evidence of progression was significantly smaller after nifedipine (14), and larger after propranolol (39) as compared with controls (24). Patients with evidence of progression of old lesions, and appearance of new lesions were significantly fewer in Group 1 than in Group 2 and in control patients. Thus, nifedipine seemed more protective than either of the other drugs against coronary atherosclerosis. The coronary risk factors were within normal limits in the nifedipine treated group and remained so with treatment supporting that they were likely dissociated from influences on atherosclerosis. The evolution, at least as judged by the number of lesions with progression, appeared significantly (p less than 0.01) worse with propranolol than with isosorbide dinitrate. This may prospect that nitrate contrasted the evolution of the disease, or that propranolol made it worse, possibly through unfavourable modifications of serum lipids (28% rise of total triglyceride and 25% decrease of HDL cholesterol were already detectable at 12 months in Group 2).

摘要

钙拮抗剂和β受体阻滞剂可能会延缓或抑制动脉粥样硬化的形成。我们测试了硝苯地平或普萘洛尔是否可能延缓或促使人类冠状动脉粥样硬化消退。在113例患有劳力性心绞痛且已证实患有冠状动脉疾病的特定人群中,比较了硝苯地平治疗组(第1组,39例患者)、普萘洛尔治疗组(第2组,36例患者)或硝酸异山梨酯治疗组(对照组,38例患者)经过2年治疗后的冠状动脉血管造影模式与治疗前的模式。2年后,3组疾病的进展程度有所不同。与对照组(24例)相比,硝苯地平治疗后有进展证据的病变数量显著减少(14例),而普萘洛尔治疗后有进展证据的病变数量增加(39例)。第1组中旧病变有进展证据且出现新病变的患者明显少于第2组和对照组患者。因此,硝苯地平在预防冠状动脉粥样硬化方面似乎比其他两种药物更具保护作用。硝苯地平治疗组的冠状动脉危险因素在正常范围内,且治疗后仍保持如此,这支持它们可能与对动脉粥样硬化的影响无关。至少从有进展的病变数量判断,普萘洛尔治疗后的疾病进展明显(p<0.01)比硝酸异山梨酯更差。这可能预示着硝酸盐可抑制疾病进展,或者普萘洛尔可能使其恶化,可能是通过对血脂的不利改变(第2组在12个月时总甘油三酯已可检测到升高28%,高密度脂蛋白胆固醇降低25%)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验